Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)

被引：0

作者：

Roden, Michael W. ^{[1
,2
]}

Weng, Jianping ^{[3
]}

Merker, Ludwig ^{[4
]}

Christiansen, Anita Vedel ^{[5
]}

Roux, Flavien ^{[6
]}

Salsali, Afshin ^{[7
]}

Kim, Gabriel ^{[7
]}

Stella, Peter ^{[7
]}

Woerle, Hans-Juergen ^{[7
]}

Broedl, Uli C. ^{[7
]}

机构：

[1] German Diabet Ctr, Dusseldorf, Germany

[2] Heinrich Heine Univ, Dusseldorf, Germany

[3] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China

[4] Diabet & Nierenzentrum, Dormagen, Germany

[5] Boehringer Ingelheim Danmark AS, Copenhagen, Denmark

[6] Boehringer Ingelheim France SAS, Reims, France

[7] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

来源：

ENDOCRINE REVIEWS | 2014年 / 35卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LBSU-1081

引用

页数：2

共 50 条

[1] Empagliflozin (EMPA) Monotherapy for ≥76 Weeks in Drug-Naive Patients with Type 2 Diabetes (T2DM)
Roden, Michael
Weng, Jianping
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2014, 63 : A69 - A69
[2] Empagliflozin Monotherapy Improves Glucose Control in Drug-Naive Patients With Type 2 Diabetes (T2DM)
Roden, Michael
Weng, Jianping
Eilbracht, Jens
Delafont, Bruno
Kim, Gabriel
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2013, 62 : A280 - A280
[3] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
Merker, Ludwig
Haering, Hans-Ulrich
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Meinicke, Thomas
Woerle, Hans-Juergen
Broedl, Uli C.
[J]. ENDOCRINE REVIEWS, 2014, 35 (03)
[4] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
Merker, Ludwig
Haering, Hans-Ulrich
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Meinicke, Thomas
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2014, 63 : A278 - A278
[5] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Pioglitazone with or without Metformin in Patients with Type 2 Diabetes (T2DM)
Kovacs, Christopher Simon
Seshiah, Veeraswamy
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans-Juergen
Broedl, Uli C.
[J]. ENDOCRINE REVIEWS, 2014, 35 (03)
[6] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Pioglitazone With or Without Metformin in Patients with Type 2 Diabetes (T2DM)
Kovacs, Christopher S.
Seshiah, Veeraswamy
Merker, Ludwig
Christiansen, Anita Vedel
Roux, Flavien
Salsali, Afshin
Kim, Gabriel
Stella, Peter
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2014, 63 : A273 - A273
[7] Empagliflozin monotherapy in drug-naive patients with Type 2 diabetes
Roden, M.
Weng, J.
Merker, L.
Christiansen, A. Vedel
Roux, F.
Salsali, A.
Kim, G.
Stella, P.
Woerle, H. J.
Broedl, U. C.
[J]. DIABETIC MEDICINE, 2015, 32 : 89 - 89
[8] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin Plus Sulfonylurea (SU) in Patients with Type 2 Diabetes (T2DM)
Haering, Hans-Ulrich
Merker, Ludwig
Vedel, Anita
Roux, Christiansen Flavien
Salsali, Afshin
Kim, Gabriel
Meinicke, Thomas
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2014, 63 : A280 - A280
[9] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
Kohler, S.
Kaspers, S.
Salsali, A.
Zeller, C.
Woerle, H. -J.
[J]. DIABETOLOGIA, 2016, 59 : S26 - S26
[10] Empagliflozin Monotherapy for 12 Weeks Improves Glycemic Control in Japanese Patients With Type 2 Diabetes (T2DM)
Kadowaki, Takashi
Haneda, Masakazu
Inagaki, Nobuya
Taniguchi, Atsushi
Sakamoto, Masashi
Koiwai, Kazuki
Rattunde, Henning
Woerle, Hans J.
Broedl, Uli C.
[J]. DIABETES, 2013, 62 : A297 - A298

← 1 2 3 4 5 →